Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer Portfolio News / By Karina Tin August 24, 2021
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research Portfolio News / By Karina Tin August 23, 2021
Remix Therapeutics Names Peter Smith, PhD, as President and Chief Executive Officer Portfolio News / By Karina Tin August 17, 2021
RAPT Therapeutics Reports Second Quarter 2021 Financial Results Portfolio News / By Karina Tin August 11, 2021
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin August 11, 2021
Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration Portfolio News / By Karina Tin August 11, 2021
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update Portfolio News / By Karina Tin August 10, 2021
Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth Portfolio News / By Karina Tin August 5, 2021
NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results Portfolio News / By Karina Tin August 5, 2021
eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer Portfolio News / By Karina Tin August 4, 2021
